

PTAG (S-15): sc-86807

BACKGROUND

PTAG (pituitary tumor derived apoptosis gene), also known as RHBDD3 (rhomboid domain containing 3), is a novel 386 amino acid multi-pass membrane protein that contains one UBA domain and augments drug-induced apoptosis. Cells lacking PTAG have a reduced apoptotic response, thereby causing a predisposition to cell malignancy and resistance to chemotherapeutic interventions, and PTAG plays a role in colorectal tumorigenesis as the majority of primary colorectal tumors lack the PTAG gene. Encoded by a gene located on human chromosome 22, PTAG is often co-expressed with EWS (ewing sarcoma breakpoint region 1), a gene located directly downstream of PTAG.

REFERENCES

- Collins, J.E., Goward, M.E., Cole, C.G., Smink, L.J., Huckle, E.J., Knowles, S., Bye, J.M., Beare, D.M. and Dunham, I. 2003. Reevaluating human gene annotation: a second-generation analysis of chromosome 22. *Genome Res.* 13: 27-36.
- Bahar, A., Simpson, D.J., Cutty, S.J., Bicknell, J.E., Hoban, P.R., Holley, S., Mourtada-Maarabouni, M., Williams, G.T., Clayton, R.N. and Farrell, W.E. 2004. Isolation and characterization of a novel pituitary tumor apoptosis gene. *Mol. Endocrinol.* 18: 1827-1839.
- Farrell, W.E. 2005. Epigenetic mechanisms of tumorigenesis. *Horm. Metab. Res.* 37: 361-368.
- Farrell, W.E. 2006. A novel apoptosis gene identified in the pituitary gland. *Neuroendocrinology* 84: 217-221.
- Bahar, A., Whitby, P., Holley, S., Hoban, P.R., Elder, J.B., Deakin, M., Hall, C., Clayton, R.N., Williams, G.T. and Farrell, W.E. 2007. Primary colorectal tumors fail to express the proapoptotic mediator PTAG and its reexpression augments drug-induced apoptosis. *Genes Chromosomes Cancer.* 46: 202-212.
- Möller, E., Mandahl, N., Iliszko, M., Mertens, F. and Panagopoulos, I. 2009. Bidirectionality and transcriptional activity of the EWSR1 promoter region. *Oncol. Rep.* 21: 641-648.

CHROMOSOMAL LOCATION

Genetic locus: RHBDD3 (human) mapping to 22q12.1; Rhbdd3 (mouse) mapping to 11 A1.

SOURCE

PTAG (S-15) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within an internal region of PTAG of human origin.

PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-86807 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

PTAG (S-15) is recommended for detection of PTAG of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for PTAG siRNA (h): sc-76284, PTAG siRNA (m): sc-152569, PTAG shRNA Plasmid (h): sc-76284-SH, PTAG shRNA Plasmid (m): sc-152569-SH, PTAG shRNA (h) Lentiviral Particles: sc-76284-V and PTAG shRNA (m) Lentiviral Particles: sc-152569-V.

Molecular Weight of PTAG: 41 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.